首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >The mechanism of topoisomerase I poisoning by a camptothecin analog
【24h】

The mechanism of topoisomerase I poisoning by a camptothecin analog

机译:喜树碱类似物使拓扑异构酶I中毒的机理

获取原文
获取原文并翻译 | 示例
       

摘要

We report the x-ray crystal structure of human topoisomerase I covalently joined to double-stranded DNA and bound to the clinically approved anticancer agent Topotecan. Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (-1) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme-substrate complex, Topotecan acts as an uncom-petitive inhibitor. The structure can explain several of the known structure-activity relationships of the camptothecin family of anticancer drugs and suggests that there are at least two classes of mutations that can produce a drug-resistant enzyme. The first class includes changes to residues that contribute to direct interactions with the drug, whereas a second class would alter interactions with the DNA and thereby destabilize the drug-binding site.
机译:我们报告了人类拓扑异构酶I的X射线晶体结构,该结构共价结合到双链DNA并与临床批准的抗癌药Topotecan结合。托泊替康模拟DNA碱基对,并通过在上游(-1)和下游(+1)碱基对之间插入而在DNA切割位点结合。插层置换了下游DNA,从而阻止了切割链的重新连接。通过与酶-底物复合物特异性结合,托泊替康充当了非竞争性抑制剂。该结构可以解释喜树碱抗癌药物家族的几种已知的构效关系,并表明至少有两类突变可以产生抗药性酶。第一类包括对残基的改变,这些改变有助于与药物直接相互作用,而第二类将改变与DNA的相互作用,从而使药物结合位点不稳定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号